Cenegermin
未知生产厂商
Cenegermin is a recombinant human nerve growth factor used to treat neurotrophic keratitis.
Cenegermin is a recombinant human nerve growth factor used to treat neurotrophic keratitis.
Cenegermin is a recombinant form of human nerve growth factor . Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation . The loss of corneal sensation impairs corneal health causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and perforation in severe cases . Nerve growth factor is subsequently an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors . Nerve growth factor receptors are expressed in the anterior segment of the eye (cornea, conjunctiva, iris, ciliary body, and lens), by the lacrimal gland, and by posterior segment intraocular tissues . The treatment with cenegermin, administered as eye drops, is intended to allow restoration of corneal integrity .
Cenegermin is indicated for the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults .
共 1 项相关疾病
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物,而非通用名;且专利申请在提交约 18 个月后才公开,较新的药物可能尚未出现在这里。